drugset / Trial / NCT01959334
Evaluate the Immunogenicity of a Novel Glucagon Formulation
RandomizedParallel-groupOpen-labelOther
Summary
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.
Timeline
- Start
- 2013-09
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glucagon | Peptide | 1 mg | Intranasal |
| Subject | Glucagon | Peptide | 3 mg | Intranasal |